Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Previous Page

Next Page

Page Background

Outline

•

Next generation ALK TKI new SoC in 1

st

line

•

The brain is the issue

•

PFS improvement correlates with OS?

•

Best upfront

vs

. options at PD

•

Can we personalise treatment upfront?